tiprankstipranks
Advertisement
Advertisement

CLLS Stock Latest News

Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
Company AnnouncementsCellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
20d ago
6K
CLLS
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
PremiumCompany Announcements
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
28d ago
6K
CLLS
CLLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CLLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
CLLS
Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027
PremiumCompany Announcements
Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027
3M ago
6K
CLLS
Cellectis initiated with a Buy at Clear Street
PremiumThe Fly
Cellectis initiated with a Buy at Clear Street
4M ago
CLLS
Cellectis Announces Arbitral Decision in Servier Dispute
PremiumCompany AnnouncementsCellectis Announces Arbitral Decision in Servier Dispute
4M ago
6K
CLLS
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
Premium
The Fly
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
4M ago
ALLO
CLLS
Cellectis announces arbitral decision in dispute with Servier
Premium
The Fly
Cellectis announces arbitral decision in dispute with Servier
4M ago
CLLS
Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
PremiumCompany Announcements
Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
4M ago
6K
CLLS
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
PremiumCompany Announcements
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
4M ago
6K
CLLS
Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
PremiumCompany Announcements
Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
5M ago
6K
CLLS
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
PremiumRatings
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
5M ago
CLLS
Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025
PremiumCompany AnnouncementsCellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025
5M ago
6K
CLLS
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
Premium
The Fly
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
5M ago
CLLS
CLLS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
CLLS Earnings this Week: How Will it Perform?
5M ago
CLLS
Cellectis Showcases Promising Clinical Trial Data at ASH 2025
PremiumCompany Announcements
Cellectis Showcases Promising Clinical Trial Data at ASH 2025
5M ago
6K
CLLS
Cellectis to present development update for eti-cel at ASH 2025
PremiumThe Fly
Cellectis to present development update for eti-cel at ASH 2025
5M ago
CLLS
Cellectis to Announce Q3 2025 Financial Results on November 7
PremiumCompany Announcements
Cellectis to Announce Q3 2025 Financial Results on November 7
5M ago
6K
CLLS
Cellectis price target raised to $4 from $3 at Wells Fargo
PremiumThe Fly
Cellectis price target raised to $4 from $3 at Wells Fargo
6M ago
CLLS
Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL
PremiumCompany AnnouncementsCellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL
6M ago
6K
CLLS
Cellectis price target raised to $8 from $4 at Barclays
Premium
The Fly
Cellectis price target raised to $8 from $4 at Barclays
6M ago
CLLS
Cellectis Showcases Pipeline Progress at R&D Day
Premium
Company Announcements
Cellectis Showcases Pipeline Progress at R&D Day
6M ago
6K
CLLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >